# OncoPep

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncopep

- Industry: Pharmaceuticals
- Headquarters: North Andover, US
- Website: www.oncopep.com
- Total disclosed funding: $11M
- Latest round: Series D (Dec 10, 2021)
- Investors on record: 4

## About

OncoPep, Inc. is a biotechnology company focused on developing innovative therapeutics to address unmet medical needs in oncology. Their mission is to improve cancer treatment outcomes through targeted therapies.OncoPep, Inc. was founded in 2010 in North Andover, US, and specializes in oncology therapeutics. The company has undergone strategic development to enhance its product offerings and has not reported any major pivots in its business operations. Jooeun Bae is the founder of OncoPep, while Doris Peterkin serves as the CEO. The company has successfully raised USD 11.00 mn in its latest funding round, the Series D, on December 10, 2021, with participation from investors such as Kukje Pharm Co., Ltd and Crystal Bioscience.OncoPep specializes in developing innovative therapeutics aimed at addressing unmet medical needs within the oncology sector. Their primary offerings include a suite of proprietary drug candidates that are engineered to target specific cancer types, enhancing treatment efficacy while minimizing side effects. These products are designed for use by healthcare professionals in clinical settings, with end-users being patients diagnosed with various forms of cancer. The company's therapeutic solutions are aimed at improving patient outcomes, particularly in cases where conventional treatments have proven ineffective. OncoPep actively markets its products in North America and select European countries, targeting hospitals, oncology clinics, and research institutions to broaden its reach and impact.OncoPep generates revenue primarily through direct sales of its therapeutic products to healthcare providers and institutions engaged in cancer treatment. The transactions are structured around a direct-to-consumer model, focusing on partnerships with hospitals and oncology practices that require innovative treatment options for their patients. Clients enter into agreements that outline product pricing, availability, and delivery schedules. While specific pricing details for products are not disclosed, the revenue structure emphasizes strategic collaborations and possibly subscription services for ongoing access to their drug candidates. This model allows for stability in revenue flow as healthcare providers utilize OncoPep's therapies in their treatment protocols.OncoPep plans to utilize the USD 11.00 mn raised in its Series D funding to support ongoing clinical trials and advance its pipeline development. The company is focused on designing and launching new therapeutic products tailored to specific cancer types, with anticipated releases aligned with its clinical trial progress. Additionally, OncoPep aims to expand its market presence beyond North America into select European regions, targeting key hospitals and oncology clinics by 2023.

## Funding rounds

- Series D, Dec 10, 2021, $11M — Crystal Bioscience, Terra Science Co., Ltd., Kukje Pharm Co., Ltd, SX Company

## Investors

- Crystal Bioscience (https://capitalatlas.ai/funds/crystal-bioscience) — Series D
- Terra Science Co., Ltd. — Series D
- Kukje Pharm Co., Ltd — Series D
- SX Company — Series D